메뉴 건너뛰기




Volumn 124, Issue 5, 2014, Pages 771-779

The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD34 ANTIGEN; IMIDAZOLINE DERIVATIVE; JANUS KINASE 2; PEGINTERFERON ALPHA2A; PROTEIN P53; RG 7112; UNCLASSIFIED DRUG;

EID: 84905088528     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-536854     Document Type: Article
Times cited : (55)

References (38)
  • 1
    • 13544275273 scopus 로고    scopus 로고
    • The polycythemias
    • Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Philadelphia, PA: Churchill Livingstone
    • Hoffman R, Xu M, Finazzi G, Barbui T. The polycythemias. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2008:1073-1108.
    • (2008) Hematology: Basic Principles and Practice , pp. 1073-1108
    • Hoffman, R.1    Xu, M.2    Finazzi, G.3    Barbui, T.4
  • 2
    • 0141498506 scopus 로고    scopus 로고
    • Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders
    • Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002;76(Suppl 2):193-203.
    • (2002) Int J Hematol. , vol.76 , Issue.SUPPL. 2 , pp. 193-203
    • Mesa, R.A.1
  • 3
    • 0037114625 scopus 로고    scopus 로고
    • Polycythemia vera: Myths, mechanisms, and management
    • DOI 10.1182/blood-2001-12-0349
    • Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-4290. (Pubitemid 35429665)
    • (2002) Blood , vol.100 , Issue.13 , pp. 4272-4290
    • Spivak, J.L.1
  • 4
    • 9644275709 scopus 로고    scopus 로고
    • Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
    • DOI 10.1016/j.blre.2004.02.002, PII S0268960X04000141
    • Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005;19(1):1-13. (Pubitemid 39574245)
    • (2005) Blood Reviews , vol.19 , Issue.1 , pp. 1-13
    • Kralovics, R.1    Skoda, R.C.2
  • 5
    • 84883185991 scopus 로고    scopus 로고
    • Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a
    • Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013;122(6):893-901.
    • (2013) Blood. , vol.122 , Issue.6 , pp. 893-901
    • Quintás-Cardama, A.1    Abdel-Wahab, O.2    Manshouri, T.3
  • 6
    • 54049141336 scopus 로고    scopus 로고
    • Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
    • Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
    • (2008) Blood. , vol.112 , Issue.8 , pp. 3065-3072
    • Kiladjian, J.J.1    Cassinat, B.2    Chevret, S.3
  • 7
    • 56249104095 scopus 로고    scopus 로고
    • Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms
    • Kiladjian J-J, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22(11):1990-1998.
    • (2008) Leukemia. , vol.22 , Issue.11 , pp. 1990-1998
    • Kiladjian, J.-J.1    Chomienne, C.2    Fenaux, P.3
  • 8
    • 79955947379 scopus 로고    scopus 로고
    • The renaissance of interferon therapy for the treatment of myeloid malignancies
    • Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117(18):4706-4715.
    • (2011) Blood. , vol.117 , Issue.18 , pp. 4706-4715
    • Kiladjian, J.J.1    Mesa, R.A.2    Hoffman, R.3
  • 10
    • 33746307253 scopus 로고    scopus 로고
    • Long-term effects of the treatment of polycythemia vera with recombinant interferon-α
    • DOI 10.1002/cncr.22026
    • Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer. 2006;107(3):451-458. (Pubitemid 44107203)
    • (2006) Cancer , vol.107 , Issue.3 , pp. 451-458
    • Silver, R.T.1
  • 11
    • 73949090770 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
    • Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418-5424.
    • (2009) J Clin Oncol. , vol.27 , Issue.32 , pp. 5418-5424
    • Quintás-Cardama, A.1    Kantarjian, H.2    Manshouri, T.3
  • 12
    • 81255210738 scopus 로고    scopus 로고
    • A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms
    • Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637-655.
    • (2011) Expert Rev Hematol. , vol.4 , Issue.6 , pp. 637-655
    • Hasselbalch, H.C.1
  • 13
    • 84867750834 scopus 로고    scopus 로고
    • Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells
    • Lu M, Wang X, Li Y, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120(15):3098-3105.
    • (2012) Blood. , vol.120 , Issue.15 , pp. 3098-3105
    • Lu, M.1    Wang, X.2    Li, Y.3
  • 14
    • 78549243371 scopus 로고    scopus 로고
    • Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells
    • Lu M, Wang J, Li Y, et al. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 2010;116(20):4284-4287.
    • (2010) Blood. , vol.116 , Issue.20 , pp. 4284-4287
    • Lu, M.1    Wang, J.2    Li, Y.3
  • 15
    • 84863652338 scopus 로고    scopus 로고
    • Roles of p53 in various biological aspects of hematopoietic stem cells
    • Nii T, Marumoto T, Tani K. Roles of p53 in various biological aspects of hematopoietic stem cells. J Biomed Biotechnol. 2012;2012:903435.
    • (2012) J Biomed Biotechnol , vol.2012 , pp. 903435
    • Nii, T.1    Marumoto, T.2    Tani, K.3
  • 16
    • 0033060788 scopus 로고    scopus 로고
    • IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines
    • DOI 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1
    • Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P; International Agency for Research on Cancer. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. Hum Mutat. 1999;14(1):1-8. (Pubitemid 29309938)
    • (1999) Human Mutation , vol.14 , Issue.1 , pp. 1-8
    • Hernandez-Boussard, T.1    Rodriguez-Tome, P.2    Montesano, R.3    Hainaut, P.4
  • 17
    • 0036785106 scopus 로고    scopus 로고
    • N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders
    • Tsurumi S, Nakamura Y, Maki K, et al. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol. 2002;71(2):131-133.
    • (2002) Am J Hematol. , vol.71 , Issue.2 , pp. 131-133
    • Tsurumi, S.1    Nakamura, Y.2    Maki, K.3
  • 20
    • 77952955507 scopus 로고    scopus 로고
    • Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
    • Lu M, Zhang W, Li Y, et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010;38(6):472-480.
    • (2010) Exp Hematol. , vol.38 , Issue.6 , pp. 472-480
    • Lu, M.1    Zhang, W.2    Li, Y.3
  • 21
    • 78650638268 scopus 로고    scopus 로고
    • SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis
    • Li Y, Matsumori H, Nakayama Y, et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells. 2011;16(1):34-45.
    • (2011) Genes Cells. , vol.16 , Issue.1 , pp. 34-45
    • Li, Y.1    Matsumori, H.2    Nakayama, Y.3
  • 22
    • 33845901313 scopus 로고    scopus 로고
    • MDM2 inhibitors for cancer therapy
    • DOI 10.1016/j.molmed.2006.11.002, PII S1471491406002590
    • Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13(1):23-31. (Pubitemid 46027725)
    • (2007) Trends in Molecular Medicine , vol.13 , Issue.1 , pp. 23-31
    • Vassilev, L.T.1
  • 23
    • 79551474361 scopus 로고    scopus 로고
    • MDM2 and MDMX in cancer and development
    • Marine JC. MDM2 and MDMX in cancer and development. Curr Top Dev Biol. 2011;94:45-75.
    • (2011) Curr Top Dev Biol. , vol.94 , pp. 45-75
    • Marine, J.C.1
  • 24
    • 84858008200 scopus 로고    scopus 로고
    • JAK2 (V617F) negatively regulates p53 stabilization by enhancing MDM2 via la expression in myeloproliferative neoplasms
    • Nakatake M, Monte-Mor B, Debili N, et al. JAK2 (V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31(10):1323-1333.
    • (2012) Oncogene. , vol.31 , Issue.10 , pp. 1323-1333
    • Nakatake, M.1    Monte-Mor, B.2    Debili, N.3
  • 26
    • 79960381235 scopus 로고    scopus 로고
    • A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL)
    • Andreeff M, Kojima K, Padmanabhan S, et al. A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). ASH Annual Abstracts. 2010;116:657.
    • (2010) ASH Annual Abstracts. , vol.116 , pp. 657
    • Andreeff, M.1    Kojima, K.2    Padmanabhan, S.3
  • 28
    • 84868612626 scopus 로고    scopus 로고
    • Spleens of myelofibrosis patients contain malignant hematopoietic stem cells
    • Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012;122(11):3888-3899.
    • (2012) J Clin Invest. , vol.122 , Issue.11 , pp. 3888-3899
    • Wang, X.1    Prakash, S.2    Lu, M.3
  • 29
    • 33750611344 scopus 로고    scopus 로고
    • Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
    • Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108(9):3128-3134.
    • (2006) Blood. , vol.108 , Issue.9 , pp. 3128-3134
    • Ishii, T.1    Bruno, E.2    Hoffman, R.3    Xu, M.4
  • 31
    • 84897131066 scopus 로고    scopus 로고
    • JAK2 mutants (e.G., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
    • Gäbler K, Behrmann I, Haan C. JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAK-STAT. 2013;2(3):e25025.
    • (2013) JAK-STAT. , vol.2 , Issue.3
    • Gäbler, K.1    Behrmann, I.2    Haan, C.3
  • 32
    • 84887736491 scopus 로고    scopus 로고
    • Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis
    • Gowin K, Mesa R. Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert Opin Investig Drugs. 2013;22(12):1603-1611.
    • (2013) Expert Opin Investig Drugs. , vol.22 , Issue.12 , pp. 1603-1611
    • Gowin, K.1    Mesa, R.2
  • 33
    • 84872808860 scopus 로고    scopus 로고
    • p53 as a target in myeloproliferative neoplasms
    • Lu M, Hoffman R. p53 as a target in myeloproliferative neoplasms. Oncotarget. 2012;3(10):1052-1053.
    • (2012) Oncotarget. , vol.3 , Issue.10 , pp. 1052-1053
    • Lu, M.1    Hoffman, R.2
  • 34
    • 84880944672 scopus 로고    scopus 로고
    • Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
    • Stauffer Larsen T, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37(9):1041-1045.
    • (2013) Leuk Res. , vol.37 , Issue.9 , pp. 1041-1045
    • Stauffer Larsen, T.1    Iversen, K.F.2    Hansen, E.3
  • 35
    • 84879728130 scopus 로고    scopus 로고
    • Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
    • Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692-3702.
    • (2013) Blood. , vol.121 , Issue.18 , pp. 3692-3702
    • Mullally, A.1    Bruedigam, C.2    Poveromo, L.3
  • 36
    • 84886850069 scopus 로고    scopus 로고
    • JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa
    • Hasan S, Lacout C, Marty C, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. Blood. 2013;122(8):1464-1477.
    • (2013) Blood. , vol.122 , Issue.8 , pp. 1464-1477
    • Hasan, S.1    Lacout, C.2    Marty, C.3
  • 37
    • 79959232873 scopus 로고    scopus 로고
    • Recombinant interferon-a may retard progression of early primary myelofibrosis: A preliminary report
    • Silver RT, Vandris K, Goldman JJ. Recombinant interferon-a may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24):6669-6672.
    • (2011) Blood. , vol.117 , Issue.24 , pp. 6669-6672
    • Silver, R.T.1    Vandris, K.2    Goldman, J.J.3
  • 38
    • 67649976491 scopus 로고    scopus 로고
    • PEG-IFN-α-2a therapy in patients with myelofibrosis: A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM)
    • Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-α-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myé loprolifératifs (FIM). Br J Haematol. 2009;146(2):223-225.
    • (2009) Br J Haematol. , vol.146 , Issue.2 , pp. 223-225
    • Ianotto, J.C.1    Kiladjian, J.J.2    Demory, J.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.